National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Abiraterone acetate (Zytiga®) for mCRPC post ADT

Pharmacoeconomic evaluation of Abiratone acetate (Zytiga®) for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated

Rapid Review

Commenced Completed Outcome
03/01/2013 01/02/2013 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
26/09/2013  07/03/2014 Reimbursement not recommended at the submitted price.

Abiraterone (Zytiga) pre-chemotherapy Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.